Astromech AI

, founded in 2025 and based in the Texas, US, offers advanced artificial intelligence solutions that integrate multi-dimensional biological insights, enhancing research capabilities in genomics and biotechnology., specializes in AI-driven genomic analysis. Astromech specializes in AI-driven genomic analysis. The company was co-founded by Ben Lamm and George Church. In August 2026, Astromech AI, Corp. Astromech is advancing the fields of AI and biology with a robust platform designed to integrate multi-dimensional biological insights through state-of-the-art AI technologies. Central to their offerings are advanced systems for genomic inference, including Attention-Based Deep Learners that identify functional patterns across diverse transcriptomes, and Bayesian Ancestral Reconstruction tools that compute evolutionary trajectories. The company also focuses on a Graph-Based Pangenome to capture population-scale structural variants and is developing a Multi-Omics Integrator to provide unified insights across complex biological systems. These solutions are tailored for a variety of end users, including scientists, researchers, and engineers in medicine and agriculture, aiming to enhance their understanding of genetic information and its applications in a range of fields. The primary markets for Astromech's products span North America, Europe, and Asia, catering to both academic institutions and private sector organizations engaged in cutting-edge biological research. Astromech generates revenue through a subscription-based model, allowing clients to access its suite of AI-driven genomic analysis tools, which include flagship offerings like the Attention-Based Deep Learner and Bayesian Ancestral Reconstruction systems. The pricing structure typically involves tiered subscription plans, enabling clients to select services based on their specific research needs and scale of operation. Partnerships with organizations in life sciences, biotechnology, and agricultural sectors further enhance the company’s revenue streams by facilitating collaborative projects that leverage shared resources and expertise. Transactions are primarily conducted on a B2B basis, with clients ranging from research institutions to biotech firms, driving a steady flow of income through the utilization of advanced tools for genomic synthesis and analysis.

1. Seed

   Mar 12, 2026

   Amount

   $11M

   Investors

   Locked